As
Associate Director, Global Regulatory Affairs Clinical Strategy - Job ID: 1961
Ascendis Pharma
Full-time
Palo Alto, CA
other-general
Posted:
June 10, 2026
Location:
Palo Alto, CA, United States
Job Description
Do you want to be part of building a fully integrated biopharmaceutical company together with a team of highly skilled colleagues who are passionate about developing best-in-class therapeutics that address significant unmet medical needs? Then Ascendis Pharma is committed to support your personal development on our journey towards becoming a leading rare disease company.
Ascendis Pharma is a dynamic, fast-growing global biopharmaceutical company with locations in Denmark, Europe, and the United States. Today, we're advancing programs in Endocrinology Rare Disease and Oncology.
Here at Ascendis, we pride ourselves on exceptional science, visionary leadership, and skilled and passionate colleagues.
Guided by our core values of Patients, Science, and Passion, we use our TransCon® drug development platform to fulfill our mission of developing new and potentially best-in-class therapies to address unmet medical needs.
Our culture fosters a place where ski...
Ascendis Pharma is a dynamic, fast-growing global biopharmaceutical company with locations in Denmark, Europe, and the United States. Today, we're advancing programs in Endocrinology Rare Disease and Oncology.
Here at Ascendis, we pride ourselves on exceptional science, visionary leadership, and skilled and passionate colleagues.
Guided by our core values of Patients, Science, and Passion, we use our TransCon® drug development platform to fulfill our mission of developing new and potentially best-in-class therapies to address unmet medical needs.
Our culture fosters a place where ski...
Apply for this Job
Submit your application for the Associate Director, Global Regulatory Affairs Clinical Strategy - Job ID: 1961 position at Ascendis Pharma.
Apply Now Save for LaterJob Overview
Job Type:
Full-time
Location:
Palo Alto, United States
Posted:
June 10, 2026
Deadline:
June 21, 2026